The independent financial analyst theScreener just changed two ratings for the qualification of CARDIOVASCULAR SYSTEMS (US), active in the Medical Equipment industry. Its market behaviour has improved and can now be considered as moderately risky; its fundamental valuation receives an improved star rating and now shows 2 out of 4 stars. theScreener considers that these elements slightly improve the general evaluation, which passes therefore to Neutral. As of the analysis date April 1, 2022, the ...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
U.S. dollar breaking down; Gold breaking out The S&P 500 is consolidating under 2,954 - logical resistance - as market participants are in wait-and-see mode for incremental trade news ahead of the Trump/Xi G20 meeting later this week. While a breakout is certainly possible, we believe additional consolidation is the more likely scenario. Below we highlight a mix of positive and negative developments which lead us to this conclusion along with updates on other big picture trends. • U.S. dolla...
Summary Marketline's VentriPoint Diagnostics Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by VentriPoint Diagnostics Ltd. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive break...
Small-caps, biotech, Discretionary hitting new highs We remain bullish on the market, but to be clear, this is not a blanket endorsement. As we outline below, the “market†has pockets of strength and pockets of weakness. Our aim as always, is to highlight each and guide our clients to areas of outperformance. With that said, let's consider the weight of the evidence for the current state of our market and our bullish recommendation. • Positives. Helping support the bull case are a number...
• U.S. equity markets remain resilient. As global equity markets recover from Italian political risk, the U.S. has reasserted itself as leadership. Led by strength in technology and biotech, the Nasdaq hit a new all-time high yesterday. Small-cap indexes are also hitting all-time highs. Moreover, the S&P 500 has moved to a new high relative to May prices, providing new evidence that the market is likely to continue its trend higher. Given these developments, our outlook continues to move towar...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal third quarter, ended March 31, 2018. The company’s third-quarter revenues were $55.6 million, an increase of $3.4 million from the third- quarter of fiscal 2017. Gross profit margin rose to 82.1% from 78.6%. Prior-year gross margin included a $1.5 ...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2018 third-quarter conference call on Wednesday, May 2, 2018, at 3:45 p.m. CT (4:45 p.m. ET). CSI management will discuss results for its fiscal third quarter ended March 31, 2018, and its financial outlook. The company will issue a post-market earnings release prior to the call on May 2. To access the live webcast, go to the events section of the company’s investor relations website, https://investors....
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented 18-month outcomes from its LIBERTY 360° study at the Cardiovascular Research Technologies (CRT) 2018 interventional cardiology conference in Washington, D.C. The study evaluates the acute and long-term clinical and economic outcomes of endovascular device interventions, including CSI’s...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the OrbusNeich® 1.0mm Sapphire® II PRO coronary balloon. OrbusNeich’s 1.0mm Sapphire II PRO, the first and only 1.0mm coronary balloon available in the U.S., offers industry-leading entry ...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, announced today that the first patients were treated using its FDA-cleared extended length Diamondback 360® Peripheral Orbital Atherectomy Device (OAD) to treat peripheral artery disease (PAD). Dr. Mahir Elder, an interventional cardiologist at the Detroit Medical Center Heart Hospital, and Drs. Ian Cawich a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.